Why research matters at Colorado Blood Cancer Institute. At Colorado Blood Cancer Institute, research is more than discovery. It is part of how care moves forward. Through its collaboration with Sarah Cannon Research Institute, CBCI is helping connect patients to emerging therapies, advance early-phase blood cancer research and contribute to national conversations shaping the future of oncology care. May 14, 2026 At Colorado Blood Cancer Institute (CBCI), research is woven into patient care. It shapes how care is delivered, opens doors to new possibilities and helps move progress forward for every patient who walks through its doors. That matters deeply in blood cancer care, where treatment is evolving at a remarkable pace. New therapies, new combinations and new approaches are steadily expanding what may be possible for patients. In that environment, research is not only about discovery. It is also about access, helping connect patients to emerging options while shaping the future of cancer care. At Colorado Blood Cancer Institute, that work is supported through an embedded research infrastructure in collaboration with Sarah Cannon Research Institute (SCRI). Kelly Mozzetta, regional director of oncology research operations for CBCI and Sarah Cannon Research Institute at HCA HealthONE, a phase I drug development unit, describes a model in which regulatory specialists, coordinators, nurses, lab teams and physicians work closely together to bring clinical trials to patients in the Rocky Mountain region. Rather than operating separately, the research team is integrated into the day-to-day life of the organization and works together to support patients throughout their care journey. That level of integration matters for patients. Clinical trials can offer access to therapies that may not otherwise be available, particularly for patients whose disease has relapsed or who have exhausted standard FDA-approved treatment options. Just as important is the level of physician engagement. Mozzetta emphasizes that research involvement at Colorado Blood Cancer Institute is not limited to a small subset of providers. Instead, she describes strong engagement across the physician group, along with active work in complex and emerging areas such as early-phase blood cancer research and cellular therapy. Joshua Gordon, manager of study operations at Sarah Cannon Research Institute at HCA HealthONE, adds that Colorado Blood Cancer Institute is a leader in early-phase blood cancer research and consistently ranks among the highest-enrolling practices within the field. The recent selection of an abstract by Dr. Peter Forsberg for presentation at the 2026 American Society of Clinical Oncology (ASCO), Annual Meeting, the largest oncology conference in the world, offers one example of that culture in action. ASCO is one of the most prominent conferences in cancer care, making abstract selection a meaningful marker of scientific contribution and national visibility. More broadly, it reflects the caliber of work taking place at Colorado Blood Cancer Institute and its role in larger conversations shaping oncology care. The larger takeaway is clear: research is how cancer care advances. At Colorado Blood Cancer Institute in collaboration with Sarah Cannon Research Institute, that work is carried forward through scientific rigor, physician engagement and a shared commitment to expanding what is possible for patients. Published: May 13, 2026 May 11, 2026 Pap smear results can be confusing or scary. Learn what normal and abnormal results mean, what affects cervical cancer risk, and when follow-up testing is needed. March 03, 2026 | Amy J. Ware, MHA, MEd, FACHE January 27, 2026 Lifestyle tips and changes people can take to improve their cervical health.

Sarah Cannon Research Institute to present research on Advances in blood cancers and blood disorders at 2025 ASH Annual Meeting & Exposition. December 3, 2025 | NASHVILLE, Tenn.-(BUSINESS WIRE)-Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today that it will showcase its latest research through 100 abstracts and presentations at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9. SCRI's expansive network is represented by more than 50 researchers who serve as first authors and co-authors across over 15 research locations. A comprehensive list of SCRI abstracts and presentations at this year's Annual Meeting & Exposition can be found here. "This year's ASH Annual Meeting & Exposition marks a milestone for SCRI, with the largest number of accepted abstracts and presentations in our history," said David Spigel, MD, Chief Scientific Officer, SCRI. "This achievement reflects not only the significance of the research, but also the meaningful collaboration and unwavering commitment of the investigators across our network, all united to advance the science that transforms care for people facing blood cancers and blood disorders." * Haydar Frangoul, MD, MS, SCRI at TriStar Centennial Children's Hospital, will present "First Results of Exagamglogene Autotemcel in Pediatric Patients Aged 5-11 Years with Transfusion-Dependent Β-Thalassemia or Sickle Cell Disease with Recurrent Severe Vaso-Occlusive Crises" in an oral presentation on Saturday, December 6 at 4:00 p.m. EST in OCCC - Chapin Theatre (W320). * Dr. Frangoul is also first author on an oral presentation titled, "Enhanced CD34+ Cell Mobilizations, Collections, and Comparable Safety Profile with Fixed Dose versus Weight-Based Plerixafor Dosing in Patients with Sickle Cell Disease Receiving Autologous CD34+ Base-Edited Hematopoietic Stem Cells in the Ongoing BEACON Study" on Monday, December 8 at 5:30 p.m. EST in Hyatt - Regency Ballroom R. * Nosha Farhadfar, MD, SCRI at Methodist Healthcare, is first author on an oral presentation alongside Stephen Strickland, MD, MSCI, SCRI, and Alireza Eghtedar, MD, SCRI at Colorado Blood Cancer Institute, titled, "Promising Results from an Ongoing Phase I Multicenter Study of Senti-202, a First-In-Class, CD33 and/or FLT3 & Not Endomucin, Selective Off-The-Shelf Logic Gated CAR NK Cell Therapy in Adults with Relapsed/Refractory Acute Myeloid Leukemia" on Monday, December 8 at 5:45 p.m. EST in OCCC - Valencia Room W415BC. * Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center I The US Oncology Network, serves as first author alongside co-authors John Burke, MD, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, and Shachar Peles, MD, SCRI at Florida Cancer Specialists & Research Institute I The US Oncology Network, on an oral presentation titled, "Fixed Treatment Duration Subcutaneous Mosunetuzumab Monotherapy in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Interim Results from The Phase II MorningSun Study" on Saturday, December 6 at 9:45 a.m. EST in OCCC - Tangerine Ballroom F2. * Dr. Burke is first author alongside co-author Dr. Sharman on an oral presentation titled, "Fixed-Duration Subcutaneous Mosunetuzumab, with Maintenance Therapy, in Patients with Previously Untreated High-Tumor Burden Follicular Lymphoma: Longer Follow-Up and Exploratory Circulating Tumor DNA Analysis of The Phase II MorningSun Study" on Saturday, December 6 at 3:15 p.m. EST in OCCC - Tangerine Ballroom F2. * James Essell, MD, SCRI at OHC I The US Oncology Network, is first author on an oral titled, "Remote Therapeutic Monitoring Reduces Hospitalization due to Infection in Patients Being Treated for Hematological Malignancy" on Saturday, December 6 at 10:30 a.m. EST in OCCC - W230. * Dr. Farhadfar will deliver "Safety and Feasibility of 0.6 mg/kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study" in an oral presentation on Saturday, December 6 at 2:15 p.m. EST in OCCC - W331. In addition to scientific presentations, SCRI researchers will participate in and lead ASH Annual Meeting & Exposition sessions, including: * Hans Lee, MD, SCRI, will moderate the session, Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma, on Saturday, December 6 at 2:00 p.m. EST in OCCC - West Hall D1. * Dr. Burke will present "Engagement of Community Physicians in Clinical Trials" during the session, How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care? on Sunday, December 7 at 9:40 a.m. EST in Hyatt - Plaza Int'l HIJK.